These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38553651)

  • 21. IVIG treatment and prognosis in Guillain-Barré syndrome.
    van Doorn PA; Kuitwaard K; Walgaard C; van Koningsveld R; Ruts L; Jacobs BC
    J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S74-8. PubMed ID: 20396937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose immunoglobulin therapy for Guillain-Barré syndrome in Japanese children.
    Yata J; Nihei K; Ohya T; Hirano Y; Momoi M; Maekawa K; Sakakihara Y;
    Pediatr Int; 2003 Oct; 45(5):543-9. PubMed ID: 14521529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.
    Fokkink WR; Walgaard C; Kuitwaard K; Tio-Gillen AP; van Doorn PA; Jacobs BC
    JAMA Neurol; 2017 Feb; 74(2):189-196. PubMed ID: 28027337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes of plasma exchange versus intravenous immunoglobulin for the treatment of Guillain-Barré Syndrome: A double-blind, randomized clinical trial.
    Haridy NA; Shehab MM; Khedr EM
    Restor Neurol Neurosci; 2023; 41(5-6):203-217. PubMed ID: 38217554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study.
    Davidson AI; Halstead SK; Goodfellow JA; Chavada G; Mallik A; Overell J; Lunn MP; McConnachie A; van Doorn P; Willison HJ
    J Peripher Nerv Syst; 2017 Mar; 22(1):4-12. PubMed ID: 27801990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guillain-Barré syndrome (demyelinating) six weeks after bariatric surgery: A case report and literature review.
    Ishaque N; Khealani BA; Shariff AH; Wasay M
    Obes Res Clin Pract; 2015; 9(4):416-9. PubMed ID: 25765350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes of Serum IgG Dimer Levels after Treatment with IVIg in Guillain-Barré Syndrome.
    Svačina MKR; Röth P; Bobylev I; Sprenger A; Zhang G; Sheikh KA; Lehmann HC
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):642-648. PubMed ID: 31515689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.
    van Koningsveld R; Schmitz PI; Meché FG; Visser LH; Meulstee J; van Doorn PA;
    Lancet; 2004 Jan; 363(9404):192-6. PubMed ID: 14738791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Combination therapy with methylprednisolone (mPSL) and high-dose immunoglobulin (IVIg)].
    Nishida H; Kuroda T; Wakita K
    Nihon Rinsho; 2008 Jun; 66(6):1190-4. PubMed ID: 18540369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immunoglobulin and Guillain-Barré syndrome.
    Harel M; Shoenfeld Y
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):281-7. PubMed ID: 16391403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are Repeated Cycles of Intravenous Immunoglobulin Justified in Patients With Poorly Responsive Guillain-Barré Syndrome?
    Algahtani H; Shirah B; Alrefaei K; Albassam M; Abdelghaffar N
    Neurohospitalist; 2020 Jul; 10(3):224-228. PubMed ID: 32549948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological treatment for pain in Guillain-Barré syndrome.
    Liu J; Wang LN; McNicol ED
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD009950. PubMed ID: 25855461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological treatment for pain in Guillain-Barré syndrome.
    Liu J; Wang LN; McNicol ED
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009950. PubMed ID: 24142399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Efficacy of Intravenous Immunoglobulin in Guillain-Barré Syndrome: The Experience of a Tertiary Medical Center.
    Shalem D; Shemer A; Shovman O; Shoenfeld Y; Kivity S
    Isr Med Assoc J; 2018 Dec; 20(12):754-760. PubMed ID: 30550005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
    Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
    J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-Term Prognosis of Mechanically Ventilated Patients With Guillain-Barré Syndrome Is Worsened by Corticosteroids as an Add-On Therapy.
    Wu X; Zhang B; Li C; Shen D; Liu K; Zhu J; Zhang HL
    Medicine (Baltimore); 2015 Oct; 94(43):e1898. PubMed ID: 26512609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
    Buchwald B; Ahangari R; Weishaupt A; Toyka KV
    Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging drugs for Guillain-Barré syndrome.
    Walgaard C; Jacobs BC; van Doorn PA
    Expert Opin Emerg Drugs; 2011 Mar; 16(1):105-20. PubMed ID: 21352072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement.
    Dada MA; Kaplan AA
    Ther Apher Dial; 2004 Oct; 8(5):409-12. PubMed ID: 15663537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 44-Year-Old Hispanic Man with Loss of Taste and Bilateral Facial Weakness Diagnosed with Guillain-Barré Syndrome and Bell's Palsy Associated with SARS-CoV-2 Infection Treated with Intravenous Immunoglobulin.
    Khaja M; Gomez GPR; Santana Y; Hernandez N; Haider A; Lara JLP; Elkin R
    Am J Case Rep; 2020 Oct; 21():e927956. PubMed ID: 33128540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.